REG - Hutchmed China Ltd - Annual General Meeting Poll Results

HUTCHMED (China)Announcement

12/05/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230512:nRSL2881Za&default-theme=true

RNS Number : 2881Z  Hutchmed (China) Limited  12 May 2023

 

 

Annual General Meeting held on May 12, 2023 ¡V Poll Results

 

 

Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 12, 2023: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and
special resolution put to its Annual General Meeting ("AGM¨) held on May 12,
2023 were duly passed.  The poll results of the resolutions were as follows:

 

 

                                                                                              Number of Votes (%)*

                                                                                                                                            Passed by Shareholders

 Ordinary Resolutions

              For                                                                             Against      Withheld(#)

 1.           To consider and adopt the audited financial statements, and the reports of the  571,825,129  768                  17,055,535  Yes
              directors and independent auditors for the year ended December 31, 2022.

                                                                               (99.9999%)   (0.0001%)

 2(A).        To re-elect Mr TO Chi Keung, Simon as a director.                               561,123,049  24,976,533           2,781,850   Yes

                                                                                              (95.7385%)   (4.2615%)

 2(B).        To re-elect Dr Weiguo SU as a director.                                         587,563,585  1,275,082            42,765      Yes

                                                                                              (99.7835%)   (0.2165%)

 2(C).        To re-elect Mr CHENG Chig Fung, Johnny as a director.                           586,799,765  2,037,527 (0.3460%)  44,140      Yes

                                                                                              (99.6540%)

 2(D).        To re-elect Dr Dan ELDAR as a director.                                         585,955,689  2,882,978            42,765      Yes

                                                                                              (99.5104%)   (0.4896%)

 2(E).        To re-elect Ms Edith SHIH as a director.                                        585,511,051  3,327,616            42,765      Yes

                                                                                              (99.4349%)   (0.5651%)

 2(F).        To re-elect Mr Lefei SUN as a director.                                         585,955,594  2,883,073            42,765      Yes

                                                                                              (99.5104%)   (0.4896%)

 2(G).        To re-elect Mr Paul Rutherford CARTER as a director.                            588,835,909  1,383                44,140      Yes

                                                                                              (99.9998%)   (0.0002%)

 2(H).        To re-elect Mr Graeme Allan JACK as a director.                                 582,880,781  3,218,176            2,782,475   Yes

                                                                                              (99.4509%)   (0.5491%)

 2(I).        To re-elect Professor MOK Shu Kam, Tony as a director.                          575,206,823  13,631,844           42,765      Yes

                                                                                              (97.6850%)   (2.3150%)

 3.           To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP  588,053,284  785,368              42,780      Yes
              as the auditors of the Company for Hong Kong financial reporting and U.S.

              financial reporting purposes, respectively, and to authorize the Directors to   (99.8666%)   (0.1334%)
              fix the auditors' remuneration.

 Special Resolution
 4.           To grant a general mandate to the Directors to issue additional shares of the   580,202,630  8,636,037            42,765      Yes

            Company.^

                                                                               (98.5334%)   (1.4666%)

 Ordinary Resolution
 5.           To grant a general mandate to the Directors to repurchase shares of the         588,837,389  1,278                42,765      Yes
              Company.^

                                                                               (99.9998%)   (0.0002%)

 

*  Percentages rounded to 4 decimal places.

(#) A vote withheld is not a vote in law and is not counted in the calculation
of the proportion of the votes for and against a resolution.

^ The full text of Resolutions 4 and 5 are set out in the Notice of AGM.

 

Notes:

 

(1)       Except for Dr Karen Jean FERRANTE who had prior overseas
commitments and was unable to attend the AGM, all directors of the Company,
namely Mr TO Chi Keung, Simon, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Dr
Dan ELDAR, Ms Edith SHIH, Mr Lefei SUN, Mr Paul Rutherford CARTER, Mr Graeme
Allan JACK and Professor MOK Shu Kam, Tony, attended the AGM, either in person
or by means of electronic facilities.

 

(2)       Number of shares entitling the holders to attend and vote on
all the resolutions at the AGM: 866,131,390 shares.

 

(3)       Number of shares entitling the holders to attend and abstain
from voting in favour as set out in Rule 13.40 of the Rules Governing the
Listing of Securities on The Stock Exchange of Hong Kong Limited (the
¡§Listing Rules¡¨) at the AGM: Nil.

 

(4)       Number of shares for holders required under the Listing Rules
to abstain from voting at the AGM: Nil.

 

(5)       The scrutineer for the poll at the AGM was Computershare
Investor Services (Jersey) Limited, the Principal Share Registrar of the
Company.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President                     +852 2121 8200
 Annie Cheng, Vice President                         +1 (973) 306 4490

 Media Enquiries
 Americas - Brad Miles,                              +1 (917) 570 7340 (Mobile) / bmiles@soleburystrat.com

 Solebury Strategic Communications
 Europe - Ben Atwell / Alex Shaw,                    +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

                                                   +44 7779 545 055 (Mobile)
 FTI Consulting

                                                     / HUTCHMED@fticonsulting.com (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi, Brunswick                           +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley  / Daphne Zhang,   +44 (20) 7886 2500

 Panmure Gordon

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMSFAFFEEDSELI